Document is current
Any future updates will be listed below
-
Authors
Stege, Jacqueline A. ter
Engelhardt, Ellen G.
Woerdeman, Leonie A.E.
Oldenburg, Hester S.A.
Kieffer, Jacobien M.
Hahn, Daniela E.E.
van Duijnhoven, Frederieke H.
van Huizum, Martine A.
The, Regina
Karssen, Klemens
Kuenen, Marianne
Gerritsma, Miranda A.
(PQ) Ruhe, Quinten
Krabbe-Timmerman, Irene S.
Riet, Martijne van’t
(AN) Kimmings, Nikola
Corten, Eveline M.L.
Sherman, Kerry A.
Witkamp, Arjen J.
Bleiker, Eveline M.A.
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (A6C/NKI 2014–7031)
- License Information
-
More Information
Article History
Received: 9 May 2023
Accepted: 18 December 2024
First Online: 6 February 2025
Declarations
:
: This research protocol was examined by the accredited Medical Research Ethics Committee of the Netherlands Cancer Institute. They concluded that, considering the length and nature of the questionnaires, the obligation to fulfil the specific requirements of the Dutch law for Medical Research Involving Human Subjects was waived (reference: METC17.0652). Local approval was obtained from participating hospitals. All participating patients signed an informed consent form. This study was conducted in accordance with local laws and regulations.
: No details, images, or videos of patients are presented in the manuscript. The people depicted in Fig. 1 are co-authors and a colleague who have consented to the use of their image for the purpose of this study.
: R. The is co-founder and CEO of ZorgKeuzeLab. K. Karssen is co-founder and technical director of ZorgKeuzeLab. After trial completion, ZorgKeuzeLab will request user fees from hospitals to implement the decision aid. Under certain conditions, the NKI-AVL will receive a percentage of these user fees. None of the other authors have competing interests.
